Biospecimen

样本核心为项目1-5以及未来的试点和发展项目提供部分基础设施支助。它是为满足这些项目的需要而设计的，并作为与其他孢子合作努力的独立资源。这一核心将基于二十多年的经验，为样本收集、存储、分发和相关临床/研究信息传播提供一个组织良好和标准化的系统。组织标本的病理分析将有一致性和质量保证。此核心组的运营分为5个组成部分： 1.临床标本采集(包括手术和快速尸检的组织、血清、血浆和尿液)、加工、质量控制、储存、分发和数据库录入； 2.制定计划，不断提高生物标本采集、加工和储存的质量和效率，以提高提供给孢子调查人员的标本的保真度； 3.维护核心团队建立的27个前列腺癌异种移植株，并为孢子研究人员和合作者提供标本进行生物学研究和/或进行临床前研究； 4.实验室服务，包括制作组织微阵列、由泌尿外科病理学家解释免疫组织学、制作标本衍生品和进行PSA免疫分析以供研究； 5.一个行政计划，从少数族裔获得样本，优先分配样本，确保患者保密和遵守IRB要求，不断改进质量控制措施，并与包括孢子和P01在内的其他前列腺癌计划互动。 来自我们存储库的样本，特别是来自我们的快速尸检计划(例如前列腺癌骨转移)和我们的LuCaP系列前列腺癌异种移植的样本已经并将继续在国际上分发给其他前列腺癌研究人员。

The Specimen Core provides part of the infrastructure support for Projects 1 - 5 as well as for future pilot and developmental projects. It has been designed to meet the needs of these projects plus serve as a stand-alone resource for collaborative efforts with other SPOREs. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. The operations of this Core group into 5 components: 1. Clinical specimen acquisition (i.e. tissues, including those from surgery and the rapid autopsy program, serum, plasma and urine), processing, quality control, storage, distribution and database entry; 2. A development program to continually improve the quality and efficiency in biospecimen acquisition, processing and storage to increase the fidelity of specimens provided to the SPORE investigators; 3. Maintain 27 prostate cancer xenograft lines established by the Core team and make specimens available for biological study and/or perform pre-clinical studies for SPORE investigators and collaborators; 4. Laboratory services, including production of tissue microarrays, interpretation of immunohistology by urologic pathologists, production of specimen derivatives and perform PSA immunoassays for research; 5. An administrative program to obtain samples from minorities, prioritize the distribution of specimens, ensure patient confidentiality and compliance with IRB requirements, to continually improve quality control measures and to interact with other prostate cancer programs, including SPOREs and P01s. Specimens from our repository, especially those from our rapid autopsy program (e.g. prostate cancer bone metastases) and our LuCaP series of prostate cancer xenografts have been and will continue to be distributed to other prostate cancer investigators on an international basis.